{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:42:25Z","timestamp":1788295345824,"version":"build-2803163510"},"reference-count":112,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001771","name":"The University of Newcastle","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbcan.2025.189377","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:52:52Z","timestamp":1750967572000},"page":"189377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia"],"prefix":"10.1016","volume":"1880","author":[{"given":"Daniel L.","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop K.","family":"Enjeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa F.","family":"Lincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Skelding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark. Res."},{"issue":"10147","key":"10.1016\/j.bbcan.2025.189377_bb0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2025.189377_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100829","article-title":"AML and the art of remission maintenance","volume":"49","author":"de Lima","year":"2021","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0025","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189377_bb0030","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ijc.35125","article-title":"Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: a multicenter study from China","volume":"155","author":"Dou","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0035","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00062752-200107000-00001","article-title":"Hematologic malignancies","volume":"8","author":"Gilliland","year":"2001","journal-title":"Curr. Opin. Hematol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189377_bb0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189377_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-013-1257-4","article-title":"Gene mutations of acute myeloid leukemia in the genome era","volume":"97","author":"Naoe","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189377_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0000000000000567","article-title":"Driver mutations in acute myeloid leukemia","volume":"27","author":"Kishtagari","year":"2020","journal-title":"Curr. Opin. Hematol."},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2025.189377_bb0060","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1182\/blood-2024-207314","article-title":"Dynamic changes of genetic mutations in AML patients from diagnosis to complete remission and relapse","volume":"144","author":"Yan","year":"2024","journal-title":"Blood"},{"issue":"43","key":"10.1016\/j.bbcan.2025.189377_bb0065","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1073\/pnas.1010978107","article-title":"Accumulation of driver and passenger mutations during tumor progression","volume":"107","author":"Bozic","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0070","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1038\/s41467-021-26551-x","article-title":"Genome-wide association study identifies susceptibility loci for acute myeloid leukemia","volume":"12","author":"Lin","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0080","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2019000492","article-title":"Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801","volume":"4","author":"Marcucci","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189377_bb0085","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189377_bb0090","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A phase II study of azacitidine, venetoclax, and trametinib in relapsed or refractory acute myeloid leukemia harboring RAS pathway-activating mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189377_bb0100","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0105","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010098","article-title":"Antitumor effects of PRIMA-1 and PRIMA-1(met) (APR246) in hematological malignancies: still a mutant P53-dependent affair?","volume":"10","author":"Menichini","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbcan.2025.189377_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174345","article-title":"Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes","volume":"908","author":"Ghaffarnia","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189377_bb0130","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","article-title":"Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fiedler","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189377_bb0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bbcan.2025.189377_bb0140","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.2023020301","article-title":"Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG","volume":"142","author":"Loo","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189377_bb0145","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4149\/neo_2013_085","article-title":"Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3","volume":"60","author":"Mehta","year":"2013","journal-title":"Neoplasma"},{"key":"10.1016\/j.bbcan.2025.189377_bb0150","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Juarez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189377_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189377_bb0160","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm1579","article-title":"Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia","volume":"13","author":"Mullican","year":"2007","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41375-018-0174-1","article-title":"Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia","volume":"33","author":"Boudreaux","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0170","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.bbcan.2025.189377_bb0175","article-title":"NLRP3 inflammasome promotes the progression of acute myeloid leukemia via IL-1beta pathway","volume":"12","author":"Zhong","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0180","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1172\/JCI30779","article-title":"CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells","volume":"117","author":"Si","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189377_bb0185","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jmb.2019.02.001","article-title":"The KN-93 molecule inhibits calcium\/calmodulin-dependent protein kinase II (CaMKII) activity by binding to Ca(2+)\/CaM","volume":"431","author":"Wong","year":"2019","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ph12010008","article-title":"The multi-functional calcium\/calmodulin stimulated protein kinase (CaMK) family: emerging targets for anti-cancer therapeutic intervention","volume":"12","author":"Brzozowski","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0195","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3748\/wjg.v7.i5.627","article-title":"Pharmacology of tetrandrine and its therapeutic use in digestive diseases","volume":"7","author":"Li","year":"2001","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0200","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4103\/1008-682X.142134","article-title":"Tetrandrine suppresses proliferation, induces apoptosis, and inhibits migration and invasion in human prostate cancer cells","volume":"17","author":"Liu","year":"2015","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.bbcan.2025.189377_bb0205","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/DDDT.S187776","article-title":"Tetrandrine suppresses cervical cancer growth by inducing apoptosis in vitro and in vivo","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0210","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jss.2010.10.034","article-title":"Tetrandrine induces apoptosis and triggers caspase cascade in human bladder cancer cells","volume":"166","author":"Li","year":"2011","journal-title":"J. Surg. Res."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189377_bb0215","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1111\/bph.14031","article-title":"Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcing autophagy-mediated differentiation","volume":"174","author":"Liu","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/16078454.2022.2034256","article-title":"Tetrandrine overcomes drug resistance mediated by bone marrow microenvironment by regulating the expression of P-glycoprotein in acute leukemia","volume":"27","author":"Zhou","year":"2022","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0225","doi-asserted-by":"crossref","first-page":"62","DOI":"10.37349\/etat.2022.00072","article-title":"Targeting the two-pore channel 2 in cancer progression and metastasis","volume":"3","author":"Skelding","year":"2022","journal-title":"Explor. Target Antitumor Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0230","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1038\/s41467-020-17749-6","article-title":"Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis","volume":"11","author":"J\u00e4ger","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189377_bb0235","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/biomedicines10061250","article-title":"NF-\u03baB: a double-edged sword controlling inflammation","volume":"10","author":"Liu","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0240","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/ijlh.13440","article-title":"CaMKIIgamma regulates the viability and self-renewal of acute myeloid leukaemia stem-like cells by the Alox5\/NF-kappaB pathway","volume":"43","author":"Cheng","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2005.08.024","article-title":"Tetrandrine-induced apoptosis in rat primary hepatocytes is initiated from mitochondria: caspases and endonuclease G (Endo G) pathway","volume":"218","author":"Yan","year":"2006","journal-title":"Toxicology"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189377_bb0250","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00204-015-1584-8","article-title":"CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine","volume":"90","author":"Tian","year":"2016","journal-title":"Arch. Toxicol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189377_bb0255","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/aps.2013.62","article-title":"ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes","volume":"34","author":"Qi","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0260","first-page":"3383","article-title":"Clinical efficacy of acetylcysteine combined with tetrandrine tablets in the treatment of silicosis and the effect on serum IL-6 and TNF-\u03b1","volume":"18","author":"Sun","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0265","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10787-024-01452-9","article-title":"Therapeutic effects of tetrandrine in inflammatory diseases: a comprehensive review","volume":"32","author":"Song","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0270","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tips.2004.01.009","article-title":"Herbal alkaloid tetrandrine: fron an ion channel blocker to inhibitor of tumor proliferation","volume":"25","author":"Wang","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.gendis.2019.10.017","article-title":"Tetrandrine inhibits proliferation of colon cancer cells by BMP9\/ PTEN\/ PI3K\/AKT signaling","volume":"8","author":"Ya Zhou","year":"2021","journal-title":"Genes Dis."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0295","doi-asserted-by":"crossref","first-page":"e1123","DOI":"10.1038\/cddis.2014.84","article-title":"Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells","volume":"5","author":"Qiu","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189377_bb0300","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fphar.2017.00351","article-title":"Tetrandrine, an activator of autophagy, induces autophagic cell death via PKC-alpha inhibition and mTOR-dependent mechanisms","volume":"8","author":"Wong","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189377_bb0305","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2045-3701-5-4","article-title":"Tetrandrine is a potent cell autophagy agonist via activated intracellular reactive oxygen species","volume":"5","author":"Wang","year":"2015","journal-title":"Cell Biosci."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189377_bb0310","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41580-020-0241-0","article-title":"Mechanisms governing autophagosome biogenesis","volume":"21","author":"Nakatogawa","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/ijms24010563","article-title":"Bone marrow microenvironment as a source of new drug targets for the treatment of acute myeloid leukaemia","volume":"24","author":"Skelding","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189377_bb0320","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.3390\/cells10112833","article-title":"A role for the bone marrow microenvironment in drug resistance of acute myeloid leukemia","volume":"10","author":"Bolandi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189377_bb0325","article-title":"Elevated ABCB1 expression confers acquired resistance to aurora kinase inhibitor GSK-1070916 in cancer cells","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0330","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.leukres.2005.08.005","article-title":"Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia","volume":"30","author":"Xu","year":"2006","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189377_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112833","article-title":"A role for the bone marrow microenvironment in drug resistance of acute myeloid leukemia","volume":"10","author":"Bolandi","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189377_bb0340","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.18632\/oncotarget.3505","article-title":"Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189377_bb0350","article-title":"TP53 mutations in acute myeloid leukemia: still a daunting challenge?","volume":"10","author":"Molica","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0355","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0360","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","article-title":"What have we learned about TP53-mutated acute myeloid leukemia?","volume":"14","author":"Shahzad","year":"2024","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189377_bb0365","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1158\/0008-5472.CAN-04-0313","article-title":"Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1","volume":"64","author":"Meng","year":"2004","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189377_bb0370","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189377_bb0375","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3324\/haematol.2021.280153","article-title":"Decitabine salvage for TP53-mutated, relapsed\/refractory acute myeloid leukemia after cytotoxic induction therapy","volume":"107","author":"Ferraro","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0380","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0385","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0390","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41419-018-0498-9","article-title":"c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0395","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13046-018-0779-2","article-title":"Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy","volume":"37","author":"Yu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0405","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0410","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189377_bb0415","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189377_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106955","article-title":"Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis","volume":"197","author":"Tang","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189377_bb0425","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Romanian J. Morphol. Embryol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0430","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13643-020-01368-9","article-title":"Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis","volume":"9","author":"Song","year":"2020","journal-title":"Syst. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0435","first-page":"CD013348","article-title":"Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer","volume":"3","author":"Chuai","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0440","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0445","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/HYPERTENSIONAHA.122.19427","article-title":"VEGF (vascular endothelial growth factor) inhibition and hypertension: does microvascular rarefaction play a role?","volume":"80","author":"le Noble","year":"2023","journal-title":"Hypertension"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189377_bb0450","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.phymed.2016.10.021","article-title":"Tetrandrine, an alkaloid from S. tetrandra exhibits anti-hypertensive and sleep-enhancing effects in SHR via different mechanisms","volume":"23","author":"Huang","year":"2016","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189377_bb0455","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.24208","article-title":"Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats","volume":"124","author":"Chen","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22859","article-title":"FLT3, a prognostic biomarker for acute myeloid leukemia (AML): quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method","volume":"33","author":"Ampasavate","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0465","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189377_bb0470","first-page":"6766","article-title":"Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics","volume":"18","author":"Tao","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189377_bb0475","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bjc.2013.334","article-title":"Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)\/Akt signaling","volume":"109","author":"Wan","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189377_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189377_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189377_bb0285","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/cells13221838","article-title":"Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications","volume":"13","author":"Mustafa","year":"2024","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189377_bb0490","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cyto.a.24207","article-title":"Evaluation of caspase-3 activity during apoptosis with fluorescence lifetime-based cytometry measurements and phasor analyses","volume":"97","author":"Nichani","year":"2020","journal-title":"Cytometry A"},{"key":"10.1016\/j.bbcan.2025.189377_bb0495","doi-asserted-by":"crossref","first-page":"972984","DOI":"10.3389\/fonc.2022.972984","article-title":"Therapeutic potential of NR4A1 in cancer: Focus on metabolism","volume":"12","author":"Deng","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0500","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450115666141120112818","article-title":"The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms","volume":"16","author":"Wenzl","year":"2015","journal-title":"Curr. Drug Targets"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189377_bb0505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095280","article-title":"Plant alkaloid tetrandrine is a nuclear receptor 4A1 antagonist and inhibits Panc-1 cell growth in vitro and in vivo","volume":"23","author":"Lee","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0510","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.12458","article-title":"Mechanism of NLRP3 inflammasome activation","volume":"1319","author":"Sutterwala","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0515","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12964-024-01777-6","article-title":"Targeting NLRP3 inhibits AML progression by inducing PERK\/eIF2-mediated apoptosis","volume":"22","author":"Luciano","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"Supplement 1","key":"10.1016\/j.bbcan.2025.189377_bb0520","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2023-182289","article-title":"The dual inflammasome\/myddosome inhibitor HT-6184 restores erythropoiesis in MDS\/AML","volume":"142","author":"Rabinovich","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189377_bb0525","article-title":"NLRP3 inflammasome promotes the progression of acute myeloid leukemia via IL-1\u03b2 pathway","volume":"12","author":"C","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189377_bb0530","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41401-021-00693-6","article-title":"Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages","volume":"43","author":"Song","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0535","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-018-0574-8","article-title":"CAMKs support development of acute myeloid leukemia","volume":"11","author":"Kang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189377_bb0540","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2016.11.001","article-title":"Targeting calcium signaling in cancer therapy","volume":"7","author":"Cui","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189377_bb0545","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/cells12030401","article-title":"Calcium\/calmodulin-stimulated protein kinase II (CaMKII): different functional outcomes from activation, depending on the cellular microenvironment","volume":"12","author":"Rostas","year":"2023","journal-title":"Cells"},{"issue":"33","key":"10.1016\/j.bbcan.2025.189377_bb0550","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v23.i33.6111","article-title":"Ca2+\/calmodulin-dependent protein kinase II regulates colon cancer proliferation and migration via ERK1\/2 and p38 pathways","volume":"23","author":"Chen","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189377_bb0555","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1158\/0008-5472.CAN-09-3743","article-title":"Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII","volume":"70","author":"Nitzki","year":"2010","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189377_bb0560","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.18632\/oncotarget.3866","article-title":"Ca2+\/calmodulin-dependent protein kinase IIgamma enhances stem-like traits and tumorigenicity of lung cancer cells","volume":"6","author":"Chai","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189377_bb0565","doi-asserted-by":"crossref","first-page":"33132","DOI":"10.1038\/srep33132","article-title":"Phosphorylation of calcium\/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells","volume":"6","author":"Chi","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189377_bb0570","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbrc.2018.12.012","article-title":"Targeting the Ca(2+)\/calmodulin-dependent protein kinase II by tetrandrine in human liver cancer cells","volume":"508","author":"Huang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2025.189377_bb0575","first-page":"1","article-title":"Ca2+ signaling","volume":"6","author":"Jr","year":"1999","journal-title":"Basic Neurochem."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189377_bb0580","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2095-4964(17)60377-7","article-title":"Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: a retrospective clinical analysis","volume":"15","author":"Liu","year":"2017","journal-title":"J. Integr. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189377_bb0585","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11655-015-2303-2","article-title":"Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB\/c mice","volume":"22","author":"Shi","year":"2016","journal-title":"Chin. J. Integr. Med."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:59:37Z","timestamp":1761944377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0304419X25001192"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189377","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189377"}}